IL271159B2 - Synthesis of diastereomerically pure proteid phosphates - Google Patents

Synthesis of diastereomerically pure proteid phosphates

Info

Publication number
IL271159B2
IL271159B2 IL271159A IL27115919A IL271159B2 IL 271159 B2 IL271159 B2 IL 271159B2 IL 271159 A IL271159 A IL 271159A IL 27115919 A IL27115919 A IL 27115919A IL 271159 B2 IL271159 B2 IL 271159B2
Authority
IL
Israel
Prior art keywords
compound
diastereoisomer
mixture
formula
optionally substituted
Prior art date
Application number
IL271159A
Other languages
English (en)
Hebrew (he)
Other versions
IL271159B1 (en
IL271159A (en
Original Assignee
NuCana plc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by NuCana plc filed Critical NuCana plc
Publication of IL271159A publication Critical patent/IL271159A/en
Publication of IL271159B1 publication Critical patent/IL271159B1/en
Publication of IL271159B2 publication Critical patent/IL271159B2/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
    • C07H19/00—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof
    • C07H19/02—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof sharing nitrogen
    • C07H19/04—Heterocyclic radicals containing only nitrogen atoms as ring hetero atom
    • C07H19/16—Purine radicals
    • C07H19/20—Purine radicals with the saccharide radical esterified by phosphoric or polyphosphoric acids
    • C07H19/207—Purine radicals with the saccharide radical esterified by phosphoric or polyphosphoric acids the phosphoric or polyphosphoric acids being esterified by a further hydroxylic compound, e.g. flavine adenine dinucleotide or nicotinamide-adenine dinucleotide
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
    • C07H19/00—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof
    • C07H19/02—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof sharing nitrogen
    • C07H19/04—Heterocyclic radicals containing only nitrogen atoms as ring hetero atom
    • C07H19/16—Purine radicals
    • C07H19/20—Purine radicals with the saccharide radical esterified by phosphoric or polyphosphoric acids
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
    • C07H1/00—Processes for the preparation of sugar derivatives
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
    • C07H1/00—Processes for the preparation of sugar derivatives
    • C07H1/02—Phosphorylation
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
    • C07H19/00—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof
    • C07H19/02—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof sharing nitrogen
    • C07H19/04—Heterocyclic radicals containing only nitrogen atoms as ring hetero atom
    • C07H19/06—Pyrimidine radicals
    • C07H19/10—Pyrimidine radicals with the saccharide radical esterified by phosphoric or polyphosphoric acids
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02P—CLIMATE CHANGE MITIGATION TECHNOLOGIES IN THE PRODUCTION OR PROCESSING OF GOODS
    • Y02P20/00—Technologies relating to chemical industry
    • Y02P20/50—Improvements relating to the production of bulk chemicals
    • Y02P20/55—Design of synthesis routes, e.g. reducing the use of auxiliary or protecting groups

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Health & Medical Sciences (AREA)
  • Biochemistry (AREA)
  • Biotechnology (AREA)
  • General Health & Medical Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Saccharide Compounds (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
IL271159A 2017-06-14 2018-06-14 Synthesis of diastereomerically pure proteid phosphates IL271159B2 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
GBGB1709471.5A GB201709471D0 (en) 2017-06-14 2017-06-14 Diastereoselective synthesis of hosphate derivatives
PCT/GB2018/051638 WO2018229493A2 (en) 2017-06-14 2018-06-14 Synthesis of phosphate derivatives

Publications (3)

Publication Number Publication Date
IL271159A IL271159A (en) 2020-01-30
IL271159B1 IL271159B1 (en) 2023-06-01
IL271159B2 true IL271159B2 (en) 2023-10-01

Family

ID=59358400

Family Applications (3)

Application Number Title Priority Date Filing Date
IL312228A IL312228B2 (en) 2017-06-14 2018-06-14 Synthesis of phosphate derivatives
IL302559A IL302559B2 (en) 2017-06-14 2018-06-14 Synthesis of phosphate derivatives
IL271159A IL271159B2 (en) 2017-06-14 2018-06-14 Synthesis of diastereomerically pure proteid phosphates

Family Applications Before (2)

Application Number Title Priority Date Filing Date
IL312228A IL312228B2 (en) 2017-06-14 2018-06-14 Synthesis of phosphate derivatives
IL302559A IL302559B2 (en) 2017-06-14 2018-06-14 Synthesis of phosphate derivatives

Country Status (18)

Country Link
US (4) US11414452B2 (OSRAM)
EP (2) EP3638684A2 (OSRAM)
JP (4) JP7279991B2 (OSRAM)
KR (2) KR102695300B1 (OSRAM)
CN (3) CN110753697B (OSRAM)
AU (3) AU2018284131B2 (OSRAM)
BR (1) BR112019026747A2 (OSRAM)
CA (2) CA3064177A1 (OSRAM)
CL (1) CL2019003632A1 (OSRAM)
EA (1) EA201992873A1 (OSRAM)
GB (1) GB201709471D0 (OSRAM)
IL (3) IL312228B2 (OSRAM)
MA (1) MA49379A (OSRAM)
MX (3) MX390901B (OSRAM)
PH (1) PH12019502825A1 (OSRAM)
SA (1) SA519410795B1 (OSRAM)
SG (1) SG11201911543UA (OSRAM)
WO (2) WO2018229493A2 (OSRAM)

Families Citing this family (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2828326C (en) 2011-03-01 2019-05-07 Nucana Biomed Limited Phosphoramidate derivatives of 5 - fluoro - 2' - deoxyuridine for use in the treatment of cancer
LT3119794T (lt) 2014-06-25 2018-02-12 NuCana plc Kompozicija, apimanti gemcitabino provaistą
MX394059B (es) 2014-11-28 2025-03-24 NuCana plc Nuevos derivados de ester fosforamidato 3'-desoxiadenosina de 2' y/o 5' aminoacido como compuestos anti-cancer
PT3386998T (pt) 2015-12-11 2021-11-30 NuCana plc Síntese diastereosseletiva de derivados fosfato e do pró-fármaco gemcitabina nuc-10311
GB201522764D0 (en) 2015-12-23 2016-02-03 Nucana Biomed Ltd Formulations of phosphate derivatives
GB201609600D0 (en) 2016-06-01 2016-07-13 Nucuna Biomed Ltd Cancer treatments
GB201709471D0 (en) * 2017-06-14 2017-07-26 Nucana Biomed Ltd Diastereoselective synthesis of hosphate derivatives
GB201715011D0 (en) 2017-09-18 2017-11-01 Nucana Biomed Ltd Floxuridine synthesis
CN112409421A (zh) * 2020-12-01 2021-02-26 上海兆维科技发展有限公司 一种3’-磷酸酯核苷的制备方法
CN119546313A (zh) 2022-05-12 2025-02-28 努卡那有限公司 使用nuc-7738的癌症治疗
EP4630433A1 (en) 2022-12-07 2025-10-15 NuCana plc Synthesis of nucleoside derivative nuc-3373

Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2016030335A1 (en) * 2014-08-25 2016-03-03 Medivir Ab Dioxolane analogues of uridine for the treatment of cancer
WO2016083830A1 (en) * 2014-11-28 2016-06-02 Nucana Biomed Limited New 2' and/or 5' amino-acid ester phosphoramidate 3'-deoxy adenosine derivatives as anti-cancer compounds
WO2016098123A2 (en) * 2014-12-16 2016-06-23 Laurus Labs Private Ltd A recycling process for preparing (s)-2-[(substituted-phenoxy)-phenoxy- phosphorylamino] propionic acid isopropyl ester diastereomers
WO2017087517A1 (en) * 2015-11-16 2017-05-26 Demeter Therapeutics, Llc Nucleic acid prodrugs
WO2017207989A1 (en) * 2016-06-01 2017-12-07 Nucana Biomed Limited Adenosine derivatives for use in the treatment of cancer

Family Cites Families (54)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE279248C (OSRAM)
US3792039A (en) 1971-12-27 1974-02-12 Miles Lab Poly 2'-fluoro-2'-deoxyuridylic acid
US4500707A (en) * 1980-02-29 1985-02-19 University Patents, Inc. Nucleosides useful in the preparation of polynucleotides
US4357324A (en) 1981-02-24 1982-11-02 The United States Of America As Represented By The Department Of Health And Human Services Prodrug derivatives of 9β-D-arabinofuranosyl-2-fluoroadenine
US4668777A (en) * 1981-03-27 1987-05-26 University Patents, Inc. Phosphoramidite nucleoside compounds
CN1192102C (zh) 1998-01-23 2005-03-09 新生物生物公司 酶催化的治疗剂
US7462605B2 (en) 1998-01-23 2008-12-09 Celmed Oncology (Usa), Inc. Phosphoramidate compounds and methods of use
US6683061B1 (en) 1999-07-22 2004-01-27 Newbiotics, Inc. Enzyme catalyzed therapeutic activation
GB0317009D0 (en) 2003-07-21 2003-08-27 Univ Cardiff Chemical compounds
JP2008523082A (ja) 2004-12-09 2008-07-03 リージェンツ オブ ザ ユニバーシティ オブ ミネソタ 抗菌活性および抗癌活性を有するヌクレオチド
GB0505781D0 (en) 2005-03-21 2005-04-27 Univ Cardiff Chemical compounds
JP2009504704A (ja) 2005-08-15 2009-02-05 エフ．ホフマン−ラ ロシュ アーゲー 抗ウイルス４′−置換プロヌクレオチドホスホルアミダート
GB0623493D0 (en) 2006-11-24 2007-01-03 Univ Cardiff Chemical compounds
US7951789B2 (en) * 2006-12-28 2011-05-31 Idenix Pharmaceuticals, Inc. Compounds and pharmaceutical compositions for the treatment of viral infections
US7964580B2 (en) 2007-03-30 2011-06-21 Pharmasset, Inc. Nucleoside phosphoramidate prodrugs
US20090206007A1 (en) 2008-02-20 2009-08-20 Air Products And Chemicals, Inc. Process and apparatus for upgrading coal using supercritical water
JP2012514657A (ja) 2009-01-09 2012-06-28 ユニバーシテイ・カレツジ・オブ・カーデイフ・コンサルタンツ・リミテツド ウィルス感染を治療するためのグアノシンヌクレオシド化合物のホスホルアミダート誘導体
US20100249068A1 (en) 2009-03-20 2010-09-30 Alios Biopharma, Inc. Substituted nucleoside and nucleotide analogs
US8618076B2 (en) 2009-05-20 2013-12-31 Gilead Pharmasset Llc Nucleoside phosphoramidates
TWI583692B (zh) 2009-05-20 2017-05-21 基利法瑪席特有限責任公司 核苷磷醯胺
SMT201700412T1 (it) 2010-03-31 2017-11-15 Gilead Pharmasset Llc Procedimento per la cristallizzazione di (s)-isopropil 2-(((s)-(perfluorofenossi)(fenossi)fosforil)ammino)propanoato
JP5872539B2 (ja) 2010-03-31 2016-03-01 ギリアド ファーマセット エルエルシー プリンヌクレオシドホスホルアミダート
KR101995598B1 (ko) 2010-07-19 2019-07-02 길리애드 사이언시즈, 인코포레이티드 부분입체 이성질성으로 순수한 포스포라미데이트 전구약물의 제조 방법
EA025341B1 (ru) 2010-09-22 2016-12-30 Алиос Биофарма, Инк. Замещенные аналоги нуклеотидов
WO2012040126A1 (en) 2010-09-22 2012-03-29 Alios Biopharma, Inc. Substituted nucleotide analogs
PT3042910T (pt) 2010-11-30 2019-04-16 Gilead Pharmasset Llc 2'-espiro-nucleósidos para utilização na terapia da hepatite c
AU2011349278C1 (en) 2010-12-22 2017-01-19 Alios Biopharma, Inc. Cyclic nucleotide analogs
CA2828326C (en) 2011-03-01 2019-05-07 Nucana Biomed Limited Phosphoramidate derivatives of 5 - fluoro - 2' - deoxyuridine for use in the treatment of cancer
EP2890704B1 (en) 2012-08-31 2018-02-28 Novartis AG 2'-ethynyl nucleoside derivatives for treatment of viral infections
SI3150616T1 (sl) 2012-11-16 2017-08-31 University College Cardiff Consultants Limited Mešanica rp/sp gemcitabin-(fenil-(benziloksi-l-alaninil))-fosfata
HK1224229A1 (zh) 2013-06-26 2017-08-18 Alios Biopharma, Inc. 取代的核苷，核苷酸及其类似物
HRP20220911T1 (hr) 2013-09-11 2022-10-28 Emory University Sastav nukleotida i nukleozida i njihova uporaba
AU2014331863C1 (en) 2013-10-11 2019-05-16 Alios Biopharma, Inc. Substituted nucleosides, nucleotides and analogs thereof
BR112016011949A8 (pt) 2013-11-27 2020-04-28 Idenix Pharmaceuticals Llc composto, composição farmacêutica, e, uso dos mesmos”
CZ307789B6 (cs) * 2014-04-15 2019-05-09 Zentiva, K.S. Způsob výroby biologicky účinných fosforamidátových léčiv
EP3131914B1 (en) 2014-04-16 2023-05-10 Idenix Pharmaceuticals LLC 3'-substituted methyl or alkynyl nucleosides for the treatment of hcv
HRP20201264T1 (hr) 2014-06-25 2021-02-05 NuCana plc Prolijekovi gemcitabina
LT3119794T (lt) 2014-06-25 2018-02-12 NuCana plc Kompozicija, apimanti gemcitabino provaistą
ES2830784T3 (es) 2014-07-22 2021-06-04 NuCana plc Proceso para la preparación de gemcitabina-[fenil(benzoxi-L-alanil)]fosfato
GB201417644D0 (en) 2014-10-06 2014-11-19 Nucana Biomed Ltd Method of separating phosphate diastereoisomers
CN105646629A (zh) 2014-11-25 2016-06-08 广州市恒诺康医药科技有限公司 L-核苷类化合物及其应用
WO2016145142A1 (en) 2015-03-10 2016-09-15 Emory University Nucleotide and nucleoside therapeutics compositions and uses related thereto
CA2985540C (en) 2015-05-14 2021-08-24 NuCana plc Use of nuc-1031 in the treatment of cancer
CN106543252A (zh) 2015-09-16 2017-03-29 博瑞生物医药（苏州）股份有限公司 核苷氨基磷酸酯类前药的制备方法及其中间体
CN106478753A (zh) 2015-09-16 2017-03-08 博瑞生物医药（苏州）股份有限公司 一种nuc‑1031单一异构体的制备方法和用途
CN106543220A (zh) * 2015-09-16 2017-03-29 博瑞生物医药（苏州）股份有限公司 氨基磷酸酯化合物及其制备方法和晶体
JP7038653B2 (ja) 2015-10-05 2022-03-18 ニューカナ パブリック リミテッド カンパニー 併用療法
PT3386998T (pt) 2015-12-11 2021-11-30 NuCana plc Síntese diastereosseletiva de derivados fosfato e do pró-fármaco gemcitabina nuc-10311
GB201522764D0 (en) 2015-12-23 2016-02-03 Nucana Biomed Ltd Formulations of phosphate derivatives
PL3393478T3 (pl) 2015-12-23 2020-07-13 NuCana plc Terapia skojarzona
GB201609601D0 (en) 2016-06-01 2016-07-13 Nucana Biomed Ltd Phosphoramidate compounds
GB201609600D0 (en) 2016-06-01 2016-07-13 Nucuna Biomed Ltd Cancer treatments
GB201709471D0 (en) * 2017-06-14 2017-07-26 Nucana Biomed Ltd Diastereoselective synthesis of hosphate derivatives
GB201713916D0 (en) 2017-08-30 2017-10-11 Nucana Biomed Ltd Treatment regimens

Patent Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2016030335A1 (en) * 2014-08-25 2016-03-03 Medivir Ab Dioxolane analogues of uridine for the treatment of cancer
WO2016083830A1 (en) * 2014-11-28 2016-06-02 Nucana Biomed Limited New 2' and/or 5' amino-acid ester phosphoramidate 3'-deoxy adenosine derivatives as anti-cancer compounds
WO2016098123A2 (en) * 2014-12-16 2016-06-23 Laurus Labs Private Ltd A recycling process for preparing (s)-2-[(substituted-phenoxy)-phenoxy- phosphorylamino] propionic acid isopropyl ester diastereomers
WO2017087517A1 (en) * 2015-11-16 2017-05-26 Demeter Therapeutics, Llc Nucleic acid prodrugs
WO2017207989A1 (en) * 2016-06-01 2017-12-07 Nucana Biomed Limited Adenosine derivatives for use in the treatment of cancer

Non-Patent Citations (4)

* Cited by examiner, † Cited by third party
Title
MCGUIGAN, CHRISTOPHER, ET AL., PHOSPHORAMIDATE PROTIDES OF THE ANTICANCER AGENT FUDR SUCCESSFULLY DELIVER THE PREFORMED BIOACTIVE MONOPHOSPHATE IN CELLS AND CONFER ADVANTAGE OVER THE PARENT NUCLEOSIDE, 27 October 2011 (2011-10-27) *
ROSS, BRUCE S., ET AL., SYNTHESIS OF DIASTEREOMERICALLY PURE NUCLEOTIDE PHOSPHORAMIDATES, 21 October 2011 (2011-10-21) *
SERPI, MICHAELA, ET AL., SYNTHETIC APPROACHES FOR THE PREPARATION OF PHOSPHORAMIDATE PRODRUGS OF 2??DEOXYPSEUDOISOCYTIDINE, 5 May 2017 (2017-05-05) *
SIMMONS, BRYON, ET AL., MECHANISM-BASED SOLUTION TO THE PROTIDE SYNTHESIS PROBLEM: SELECTIVE ACCESS TO SOFOSBUVIR, ACELARIN, AND INX-08189, 18 April 2017 (2017-04-18) *

Also Published As

Publication number Publication date
KR20200016864A (ko) 2020-02-17
CL2019003632A1 (es) 2020-08-14
CA3065682A1 (en) 2018-12-20
MA49379A (fr) 2020-04-22
EA201992873A1 (ru) 2020-05-19
US20220402962A1 (en) 2022-12-22
AU2018284131B2 (en) 2022-04-07
JP2023095954A (ja) 2023-07-06
GB201709471D0 (en) 2017-07-26
CA3064177A1 (en) 2018-12-20
AU2022204691B2 (en) 2023-11-23
BR112019026747A2 (pt) 2020-06-30
WO2018229493A2 (en) 2018-12-20
PH12019502825A1 (en) 2020-10-26
IL302559B1 (en) 2024-05-01
MX2022003822A (es) 2022-05-25
CN110753697B (zh) 2023-10-13
IL271159B1 (en) 2023-06-01
AU2022204691A1 (en) 2022-08-04
AU2024200428A1 (en) 2024-02-08
US11414452B2 (en) 2022-08-16
IL302559A (en) 2023-07-01
IL302559B2 (en) 2024-09-01
MX2019014914A (es) 2020-02-13
JP2024138523A (ja) 2024-10-08
JP2020523381A (ja) 2020-08-06
JP7525687B2 (ja) 2024-07-30
IL271159A (en) 2020-01-30
IL312228B1 (en) 2025-02-01
KR20240127483A (ko) 2024-08-22
MX390901B (es) 2025-03-21
US20200181190A1 (en) 2020-06-11
WO2018229495A1 (en) 2018-12-20
IL312228B2 (en) 2025-06-01
CN110753697A (zh) 2020-02-04
JP7279991B2 (ja) 2023-05-23
SA519410795B1 (ar) 2023-11-19
JP7248209B2 (ja) 2023-03-29
CN110785425B (zh) 2023-11-21
AU2024200428B2 (en) 2025-10-16
SG11201911543UA (en) 2020-01-30
US20200181186A1 (en) 2020-06-11
EP3638685A1 (en) 2020-04-22
MX391332B (es) 2025-03-21
US11897913B2 (en) 2024-02-13
CN110785425A (zh) 2020-02-11
KR102695300B1 (ko) 2024-08-16
US20250171487A1 (en) 2025-05-29
CN117486959A (zh) 2024-02-02
AU2018284131A1 (en) 2020-01-16
MX2019014907A (es) 2020-02-13
EP3638684A2 (en) 2020-04-22
US12054511B2 (en) 2024-08-06
WO2018229493A3 (en) 2019-02-07
IL312228A (en) 2024-06-01
JP2020523378A (ja) 2020-08-06

Similar Documents

Publication Publication Date Title
JP7525687B2 (ja) ホスフェート誘導体の合成
AU2016367237B2 (en) Diastereoselective synthesis of phosphate derivatives and of the gemcitabine prodrug NUC-1031
EP3684780B1 (en) Floxuridine synthesis
EA047265B1 (ru) Получение фосфатных производных
EA043691B1 (ru) Получение фосфатных производных
HK1259701B (en) Diastereoselective synthesis of phosphate derivatives and of the gemcitabine prodrug nuc-1031
HK1232546B (en) Process for the preparation of gemcitabine-[phenyl(benzoxy-l-alaninyl)] phosphate
HK1232546A1 (en) Process for the preparation of gemcitabine-[phenyl(benzoxy-l-alaninyl)] phosphate